EVOMMUNE INC (EVMN) Stock Price, Forecast & Analysis
NYSE:EVMN • US30054Y1073
EVMN Key Statistics, Chart & Performance
The current stock price of EVMN is 31.57 USD. In the past month the price increased by 61.07%.
EVMN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to EVMN.
EVMN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVMN. EVMN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EVMN Financial Highlights
Over the last trailing twelve months EVMN reported a non-GAAP Earnings per Share(EPS) of -2.27. The EPS decreased by -100.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71% | ||
| ROE | -79.64% | ||
| Debt/Equity | 0 |
EVMN Forecast & Estimates
10 analysts have analysed EVMN and the average price target is 39.95 USD. This implies a price increase of 26.54% is expected in the next year compared to the current price of 31.57.
For the next year, analysts expect an EPS growth of -74.63% and a revenue growth 89.43% for EVMN
EVMN Ownership
EVMN Latest News, Press Relases and Analysis
EVMN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVMN
Company Profile
Evommune, Inc. is a clinical-stage biotechnology company. The company is headquartered in Palo Alto, California and currently employs 45 full-time employees. The company went IPO on 2025-11-06. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The firm's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The firm's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.
Company Info
EVOMMUNE INC
1841 Page Mill Road Suite 100
Palo Alto CALIFORNIA US
Employees: 45
Phone: 19252474487
EVOMMUNE INC / EVMN FAQ
Can you describe the business of EVOMMUNE INC?
Evommune, Inc. is a clinical-stage biotechnology company. The company is headquartered in Palo Alto, California and currently employs 45 full-time employees. The company went IPO on 2025-11-06. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The firm's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The firm's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.
What is the stock price of EVOMMUNE INC today?
The current stock price of EVMN is 31.57 USD. The price increased by 13.24% in the last trading session.
Does EVMN stock pay dividends?
EVMN does not pay a dividend.
How is the ChartMill rating for EVOMMUNE INC?
EVMN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about EVOMMUNE INC (EVMN) stock?
10 analysts have analysed EVMN and the average price target is 39.95 USD. This implies a price increase of 26.54% is expected in the next year compared to the current price of 31.57.
What is EVOMMUNE INC worth?
EVOMMUNE INC (EVMN) has a market capitalization of 949.63M USD. This makes EVMN a Small Cap stock.
Can you provide the short interest for EVMN stock?
The outstanding short interest for EVOMMUNE INC (EVMN) is 7.83% of its float.